bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).

Olink is integrating its automated Explore HT high-throughput proteomics workflows with SPT Labtech's Firefly liquid handling platform, the companies said on Tuesday.

As companies developed with biochemical reagents, BSBE, Leadman, Medicalsystem, Maccura, Dirui, and Zybio are still flourishing in the biochemistry field; they are also developing new products and expanding into other areas based on the biochemical diagnosis while maintaining the existing biochemical product lines.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the cobas® pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories. The cobas c 703 and cobas ISE neo analytical units offer cutting-edge features to help address some of the key challenges faced by diagnostic laboratories worldwide such as shortage of qualified staff and space limitations.

Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

With the help of proteomic profiling and machine learning, an international team led by investigators in the UK and Germany has identified a handful of blood plasma proteins associated with subsequent Parkinson's disease development, pointing to the possibility of developing blood-based biomarkers for the progressive neurodegenerative condition.

Every year 11 million people worldwide die of sepsis and 1.3 million of these deaths are attributable to antibiotic-resistant bacteria. For clinicians to rapidly optimize therapy and improve patient care, fast and accurate antimicrobial susceptibility testing (AST) results and interpretation are critical. In addition, fast AST can enable antimicrobial stewardship (AMS) programs which has the potential to reduce antimicrobial resistance (AMR), identified as a global threat by WHO.

Illumina said on Monday that it has entered into a credit agreement with JP Morgan.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. The test is designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection.

Recently, Shanghai Ranking officially released their 2024 Chinese University Rankings, which include 810 majors, 93 professional categories and 12 professional disciplines.

Thermo Fisher Scientific said Tuesday that it has signed a memorandum of understanding with Singapore’s National University Hospital (NUH) and Singapore RNA technology company Mirxes to develop and validate next-generation sequencing assays for early cancer detection in the country.

Roche has announced that the US Food and Drug Administration (FDA) has granted 501(k) clearance for the diagnostic use of its whole-slide imaging system, Roche Digital Pathology Dx.

In 2019, China's IVD market size exceeded 71 billion CNY, with a year-on-year growth of 15%, of which, the biochemical diagnosis market accounted for 23%; in 2020, China's IVD market size exceeded 100 billion CNY, of which, the biochemical diagnosis market accounted for 18%. Although the biochemical market share in 2020 is lower than that in 2019, the market size in 2020 has increased by nearly two billion CNY compared with 2019.

Chinese biotech MGI Tech and France’s SeqOne Genomics are partnering to advance an end-to-end solution for genomic testing.

Siemens Healthineers said on Monday that the firm has received CE marking for a prognostic blood test that the firm plans to launch later this year in Europe to aid the management of multiple sclerosis.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The US Food and Drug Administration has granted Emergency Use Authorization to Healgen Scientific for a point-of-care combination antigen test for COVID-19 and influenza A/B.

Roche announced this week that its Ventana PD-L1 (SP263) assay received a CE-IVDR label expansion for use as a companion diagnostic with Regeneron's Libtayo (cemiplimab) in combination with platinum-based doublet chemotherapy in lung cancer patients.

Challenge Works said Wednesday that it has awarded an £8 million prize to Sweden's Sysmex Astrego for its development of a point-of-care urinary tract infection test that delivers antibiotic susceptibility information in 45 minutes.